Search - tctmd.com

Displaying 21 - 38 of 38

Sort: Relevancy | Date

CME

Recent TAVR Updates and Upcoming Studies at ACC 2016

Everyday Antiplatelet Decisions: Making the Right Choices

CME

Everyday Antiplatelet Decisions: Making the Right Choices

Drug Eluting Stents: How Low Can Events Go? Integrating New Randomized Trial Data Into Clinical Practice

CME

Drug Eluting Stents: How Low Can Events Go? Integrating New Randomized Trial Data Into Clinical Practice

Defining Cost-Effectiveness and Quality of Life for TAVR

CME

Growing Indications for TAVR in 2018 and Beyond

Defining Cost-Effectiveness and Quality of Life for TAVR

CME

Defining Cost-Effectiveness and Quality of Life for TAVR

TMVR: Preparing For The Next Revolution

CME

TMVR: Preparing For The Next Revolution 2018

TAVR: Economics & Efficiencies

CME

TAVR: Economics & Efficiencies

TAVR: The Heart Team Approach

CME

TAVR: The Heart Team Approach

Changing Course with Anticoagulation in Secondary Prevention of CAD

CME

Changing Course with Anticoagulation in Secondary Prevention of CAD

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

CME

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

PERSPECTIVEs on CTO: New Evidence and Novel Approaches

CME

PERSPECTIVEs on CTO: New Evidence and Novel Approaches

TAVR Evolves: Are You and the Heart Team Ready?

CME

TAVR Evolves: Are You and the Heart Team Ready?

Evolving Thresholds for TAVR - Moving Down the Risk Spectrum

CME

Evolving Thresholds for TAVR - Moving Down the Risk Spectrum

Latest Data on Left Main Stenting and its Implications

CME

Latest Data on Left Main Stenting and its Implications

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

CME

A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI

The Latest Data on Expanded Indications and What it Means for Referring Cardiologists

CME

The Latest Data on Expanded Indications and What it Means for Referring Cardiologists

TAVR-Moving to Low Risk: New Devices/Strategies to Reduce Complications

CME

TAVR-Moving to Low Risk: New Devices/Strategies to Reduce Complications

Key Design Criteria For True Next Generation DES

CME

Key Design Criteria For True Next Generation DES

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.